MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: BioPharmaceuticals _ Orphan & Rare Diseases
Aruvant Sciences, Inc.
Attachments
Aruvant Sciences | Gene therapies for rare diseases.
Parents
*Architects: BioPharmaceuticals _ Orphan & Rare Diseases
*Industry: New York City
Architects: Sickle Cell and Thalassemia
Organization & Developments: Roivant
Children
Aruvant has an active research program with a lead product candidate, ARU-1801, in development for individuals suffering from sickle cell disease (SCD). ARU-1801, an investigational lentiviral gene therapy, is being studied in a Phase 1/2 clinical trial, the MOMENTUM study, as a one-time potentially curative treatment for SCD.
Aruvant Sciences, part of the Roivant family of companies, is a clinical-stage biopharmaceutical company focused on developing and commercializing gene therapies for the treatment of rare diseases.
Founded 2018
New York City, New York
Preliminary clinical data demonstrate engraftment of ARU-1801 and amelioration of SCD is possible with one dose of reduced intensity chemotherapy.
Will Chou CEO, ARUVANT SCIENCES, INC. (2021)